MedTrace Logo

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

NCT03880474 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2364

Last updated 2021-04-26

Study results available
· View outcomes & findings →

Summary

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults

Conditions

Interventions

BIOLOGICAL

MVA-NP+M1

Trial Vaccine

DRUG

Saline

Sodium Chloride Placebo

Sponsors & Collaborators

  • Clinical Network Services (CNS) Pty Ltd

    collaborator INDUSTRY

  • Barinthus Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • James Vandeleur, MD · Paratus Clinical Pty Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2019-10-15
Completion
2020-01-21

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880474 on ClinicalTrials.gov